



Celltrion, Inc.
23, Academy-ro, Yeonsu-gu, Incheon
22014 Republic of Korea
+82-32-850-5000
www.celltrion.com

Date: March 27, 2026

To:
Medicines Patent Pool Foundation
Rue de Varembe 7,
CH-1202 Geneva, Switzerland
office@medicinespatentpool.org
legal@medicinespatentpool.org

Re: Notice of Termination of License Agreement between Medicines Patent Pool and Celltrion on dolutegravir (DTG) dated 11th of April, 2018

Dear Sir/Madam,

This letter serves as a formal notice that Celltrion, Inc. (the "Licensee") has decided to terminate the License Agreement related to Dolutegravir, entered into with the Medicines Patent Pool (the "Licensor") on April 11, 2018.

Pursuant to Clause 13.12 of the Agreement, licensee hereby provides written notice of its decision to terminate the Agreement in its entirety. This termination shall become effective thirty (30) days from the date of this notice.

For your records, we would like to clarify the regulatory status for our TLD (TDF/LMV/DTG) product ("Product"):

- **Withdrawal of Global Approvals:** All relevant regulatory approvals for the Product, including US FDA and WHO Prequalification have been formally and officially withdrawn
- **Withdrawal of Local Approvals:** All country-specific registrations and marketing authorizations have also been officially withdrawn.
- **No Remaining Business Activity:** All sales activities for the Product under this Agreement have ceased.

Please acknowledge receipt of this notice. Should you have any questions regarding this termination, please contact Kunryoung Kim at kunryoung.kim@celltrion.com.

Sincerely,

A handwritten signature in black ink, appearing to be "Kunryoung Kim", written over a horizontal line.

Kunryoung Kim
Assistant Manager
Celltrion, Inc.